https://www.selleckchem.com/products/gdc6036.html
To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC). Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1. We analyzed 69 patients (male, n=51; median age, 71 years) wi
پسندیدن
اظهار نظر
اشتراک گذاری
